MET overexpression can occur via: 1) other tumor growth factors, such as EGF and interleukin-1 [25]; 2) transcription regulation by HIF-1α caused by hypoxia in the growing tumor [30]; 3) deregulation by transcription factors Ets and Sp1; or 4) downregulation of microRNAs targeting MET, such as miR-34 or miR-199a-3p [31–33]. The gene discussed is MET; the disease is neoplasm.